

# Antimalarial artesunate–mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial

Received: 11 April 2023

Accepted: 14 November 2023

Published online: 4 January 2024

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Schistosomiasis treatment entirely relies on a single drug, praziquantel, prompting research into alternative therapeutics. Here we evaluated the efficacy and safety of the antimalarial combination artesunate–mefloquine for the treatment of schistosomiasis in a proof-of-concept, pragmatic, open-label, randomized controlled trial in primary schools of six villages endemic for schistosomiasis in northern Senegal. Children (6–14 years) were eligible if *Schistosoma* eggs were detected by microscopy in urine and/or stool. In total, 726 children were randomized 1:1 to praziquantel (standard care: 40 mg kg<sup>-1</sup> single dose; *n* = 364) or to artesunate–mefloquine (antimalarial dosage: artesunate 4 mg kg<sup>-1</sup> and mefloquine 8 mg kg<sup>-1</sup> daily for three consecutive days; *n* = 362). Eight children not meeting the inclusion criteria were excluded from efficacy analysis. Median age of the remaining 718 participants was 9 years; 399 (55.6%) were male, and 319 (44.4%) female; 99.3% were infected with *Schistosoma haematobium* and 15.2% with *S. mansoni*. Primary outcomes were cure rate, assessed by microscopy, and frequency of drug-related adverse effects of artesunate–mefloquine versus praziquantel at 4 weeks after treatment. Cure rate was 59.6% (208/349) in the artesunate–mefloquine arm versus 62.1% (211/340) in the praziquantel arm. The difference of –2.5% (95% confidence interval (CI) –9.8 to 4.8) met the predefined criteria of noninferiority (margin set at 10%). All drug-related adverse events were mild or moderate, and reported in 28/361 children receiving artesunate–mefloquine (7.8%; 95% CI 5.4 to 11.0) versus 8/363 (2.2%; 95% CI 1.1 to 4.3) receiving praziquantel (*P* < 0.001). Artesunate–mefloquine at antimalarial dosage was moderately safe and noninferior to standard-care praziquantel for the treatment of schistosomiasis, predominantly due to *S. haematobium*. Multicentric trials in different populations and epidemiological settings are needed to confirm these findings. ClinicalTrials.gov identifier: [NCT03893097](https://clinicaltrials.gov/ct2/show/study/NCT03893097).

Schistosomiasis is a chronic helminth infection affecting more than 230 million individuals worldwide and causing major chronic morbidity<sup>1</sup>. About 90% of the burden lies with poor rural communities of sub-Saharan Africa, where *Schistosoma haematobium* and *Schistosoma*

*mansoni* predominate<sup>2</sup>. These two species cause organ-specific pathology of the urogenital tract and hepato-intestinal system, respectively, as well as nonspecific morbidities such as anemia, malnutrition and growth impairment<sup>3</sup>. Currently, treatment of schistosomiasis relies

✉ e-mail: [ebottieu@itg.be](mailto:ebottieu@itg.be)

on a single drug, praziquantel, which is active against adult worms of all *Schistosoma* species, simple to administer, safe, well tolerated and cheap<sup>4–6</sup>. The World Health Organization (WHO)-recommended, standard-care, 40 mg kg<sup>-1</sup> single-dose praziquantel treatment reaches an aggregated parasitological cure rate of 75% for both predominant *Schistosoma* species<sup>7,8</sup>, and egg reduction rates above the 90% threshold set for satisfactory drug efficacy<sup>9</sup>. However, praziquantel has little activity on juvenile worms, and reinfections remain an unsolved challenge, especially in high-transmission areas such as sub-Saharan Africa<sup>10</sup>. In addition, the efficacy of praziquantel is jeopardized by its extensive and increasing use for preventive chemotherapy. This strategy is based on mass drug administration (MDA) of praziquantel at regular intervals to at-risk populations (mainly primary-school-aged children) and aims to reduce infection intensity and prevent the development of severe egg-related morbidity<sup>6</sup>. There is indeed some preliminary evidence of decreased susceptibility of schistosome worms in children with high exposure to MDA<sup>11</sup>.

Research on much-needed alternative treatments is progressing slowly<sup>3,4</sup>, and new compounds are still in preclinical evaluation<sup>12</sup>. Repurposed antimalarial drugs such as artemisinin derivatives and mefloquine have demonstrated in vitro activity against *Schistosoma* adult and/or juvenile worms<sup>13,14</sup>, but the clinical efficacy of each drug as monotherapy did not reach that of praziquantel<sup>15–19</sup>. An exploratory trial suggested, however, that combining artesunate and mefloquine could be as effective as praziquantel for the treatment of schistosomiasis<sup>16</sup>, but another one did not find consistent activity<sup>20</sup>. Artesunate–mefloquine exists as a fixed-dose combination for the treatment of malaria<sup>21</sup>, and is one of the well-established artemisinin-based combination therapies (ACTs) recommended by the WHO. So far, evidence of a potential clinical activity of artesunate–mefloquine against *Schistosoma* infection remains inconclusive, although the need of a backup treatment for praziquantel is pressing. Also, having an available drug therapy with dual effects on malaria and schistosomiasis could open attractive perspectives in the case management of coinfecting individuals, as well as integrated chemoprevention for communities in the large co-endemic areas.

In this Article, we present the results of SchistoSAM, whose primary objectives were to compare the parasitological cure rate and safety of a 3-day course of the artesunate–mefloquine combination at antimalarial dosage versus the standard-care single-dose praziquantel for the treatment of schistosomiasis in African primary school-aged children<sup>22</sup>. The secondary objectives were (1) to determine the egg reduction rates by *Schistosoma* species, (2) to assess the cumulative antischistosomal efficacy and toxicity of one and two additional courses of artesunate–mefloquine, and (3) to monitor the incidence of clinical malaria and explore the frequency of *Plasmodium falciparum* infection and possible emergence of resistant markers.

Other components of the SchistoSAM study, aiming to assess the performance of novel schistosomiasis diagnostics as tools for monitoring treatment response, will be published elsewhere.

## Results

### Patient disposition

The trial took place in the primary schools of six selected villages (Yetti-Yone, Nder, Pakh, Gnith, Colona and Ronkh) in Richard Toll District, located in the northern Saint-Louis Region of Senegal. The area is co-endemic for *S. mansoni* and *S. haematobium*, with a reported prevalence of schistosomiasis of above 80% in school-aged children<sup>23</sup>. Malaria transmission is seasonal and annual incidence was 0.8/1,000 inhabitants in 2019 and in 2020 in this area<sup>24</sup>, below the threshold corresponding to very low malaria incidence (<1/1,000 inhabitants). Based on surveys in Senegalese school-aged children, the estimated prevalence of soil-transmitted helminthiasis is 8.2%, and 2–5% for hookworm infection<sup>25,26</sup>.

The selection of the six villages was made before the trial, based on a parasitological survey in primary schools that demonstrated

high schistosomiasis prevalence. During this survey, 726 primary school-aged children were enrolled from a total of 818 who were screened by parasitological examination of one urine and one stool sample (Methods). Enrollments per village were as follow: 322/360 (89.4%) in Gnith; 170/196 (86.7%) in Ronkh; 86/90 (95.6%) in Nder; 72/75 (96%) in Yetti-Yone; 58/69 (84.1%) in Colona; and 18/28 (64.3%) in Pakh.

These 726 children were enrolled and randomized at the baseline assessment (that is clinical, laboratory, parasitological and ultrasound assessment; Methods) from 29 November until 30 December 2019, but 8 children were eventually excluded from all efficacy analyses because they did not meet the inclusion criteria (Fig. 1).

The baseline characteristics of the remaining 718 participants were similar between trial arms as shown in Table 1. Median age was 9 years (interquartile range 7–11 years); 399 were male (55.6%) and 319 female (44.4%). Of all participants, 713 (99.3%) were infected with *S. haematobium*, alone (609; 84.8%) or coinfecting with *S. mansoni* (104; 14.5%). The remaining participants (5; 0.7%) had *S. mansoni* mono-infection. Most participants were asymptomatic (615; 85.7%), with gross hematuria being reported by 65 (9.0%) children. Mean hemoglobin level was 12.0 mg dl<sup>-1</sup> (95% confidence interval (CI) 11.3 to 12.7). Indirect markers of schistosomiasis morbidity were frequently found: microhematuria in 55.8% (369/661) and fecal occult blood in 24.3% (166/682) of the participants). In contrast, ultrasound abnormalities were infrequent, with urinary involvement in about 5% and liver pattern changes indicative of schistosomiasis fibrosis in less than 2% of the participants.

### Primary outcomes


Four weeks after treatment, 689 children (artesunate–mefloquine arm: 349; praziquantel arm: 340) were evaluated for parasitological efficacy; 29 participants were excluded from the per-protocol analysis (Fig. 1). As shown in Fig. 2 (and Supplementary Table 1), cure rate, as assessed by microscopy, in the artesunate–mefloquine arm was noninferior to that in the praziquantel arm (cure rate 59.6% (95% CI 54.4 to 64.6) versus 62.1% (95% CI 56.8 to 67.1); cure rate difference: –2.5% (95% CI –9.7 to 4.8), within the pre-established 10% margin of noninferiority; Methods). Per-species analysis revealed that artesunate–mefloquine was noninferior to praziquantel for *S. haematobium* infection (cure rate 60.8% (95% CI 55.5 to 65.8) versus 62.7% (95% CI 57.4 to 67.6), respectively; cure rate difference: –1.9% (95% CI –9.1 to 5.4)), but this could not be confirmed for the smaller number of children infected with *S. mansoni* (cure rate 88.9% (95% CI 77.8% to 94.8%) versus 96.2% (95% CI 87.0–98.9); cure rate difference: –7.3% (95% CI –18.7 to 3.6)).

For the safety analysis (Table 2), up to 4 weeks post-treatment, 28 drug-related adverse events (AEs) were reported in the 361 children who received at least one artesunate–mefloquine dose (7.8%; 95% CI 5.4 to 11.0), a higher frequency when compared with 8 occurrences in the 363 participants who got praziquantel (2.2%; 95% CI 1.1–4.3;  $P < 0.001$ ). All artesunate–mefloquine-related AEs were mild or moderate and consisted mainly of abdominal pain and vomiting. Neurological AEs were rare and mild (Table 2).

### Secondary outcomes

As reported in Table 3, the arithmetic egg reduction rates were 93.0% (95% CI 89.2 to 95.2) and 94.4% (95% CI 82.2 to 98.8) at week 4 after artesunate–mefloquine administration for *S. haematobium* and *S. mansoni*, respectively, with no statistical difference compared with those obtained with praziquantel (94.1% (95% CI 90.7 to 95.7) and 98.5% (95% CI 93.9 to 100), respectively). The geometric egg reduction rates was nearly equal between arms for *S. haematobium* (85%) and for *S. mansoni* (96%).

The cure rate, 4 weeks after the second and third administration of artesunate–mefloquine, is also reported in Fig. 3 and Supplementary Table 2. It increased from 59.6% (95% CI 54.4 to 64.6) after the first course to 76.4% (95% CI 71.6 to 80.6; cure rate difference week 10 – week 4: 16.8% (95% CI 9.9 to 23.5)) after the second dose, and to 87.4% (95% CI 83.4–90.5; cure rate difference week 16 – week 4: 27.8% (95% CI



**Fig. 1 | CONSORT flow diagram of the SchistoSAM trial and analysis population.** AM, artesunate–mefloquine; PZQ, praziquantel; ITT, intention to treat; PP, per protocol.

21.4 to 33.8)) after the third dose. Increase of cure rate was observed for both species, but was more pronounced for *S. haematobium* infection (Fig. 3). Of note, at week 16 and week 24, cure rate was higher in the repeated artesunate–mefloquine arm (87.4% and 83.9%, respectively) than in the single-dose praziquantel arm (78.4% and 75.7%, respectively) (Supplementary Table 2). In addition to the 28 drug-related AEs reported within 4 weeks after the first artesunate–mefloquine course,

only 8 new AEs were attributed to the second or third courses and all were reported as mild or moderate (Table 2). The rate of drug-related AEs increased from an initial 7.8% (up to week 4) to 10% in total for all three courses (up to week 16), with no notable change in the pattern of symptom. Of note, 80% of all reported AEs occurred within 1 week after each drug administration. Median duration of artesunate–mefloquine-related AEs was 3 days compared with 2.5 days for

**Table 1 | Baseline characteristics of study participants in the intent-to-treat analysis (n=718)**

	Total (n=718)	AM (n=360)	PZQ (n=358)
Male gender	399 (55.6)	197 (54.7)	202 (56.4)
Female gender	319 (44.4)	163 (45.3)	156 (43.6)
Age (years), median (IQR)	9.00 (7.00 to 11.0)	9.00 (7.00 to 11.0)	9.00 (7.00 to 11.0)
Height (cm), median (IQR)	132 (123 to 141)	133 (123 to 142)	131 (122 to 140)
Weight (kg), median (IQR)	25.0 (21.0 to 31.0)	25.0 (21.0 to 31.0)	25.0 (21.0 to 30.0)
<i>Schistosoma</i> species			
Single <i>S. haematobium</i> infection	609 (84.8)	306 (85.0)	303 (84.6)
Single <i>S. mansoni</i> infection	5 (0.70)	5 (1.39)	0 (0.00)
Mixed infection	104 (14.5)	49 (13.6)	55 (15.4)
Schistosomiasis infection intensity <sup>a</sup>			
<i>S. haematobium</i>			
Light (<50 eggs per 10 ml urine)	585 (81.5)	294 (81.7)	291 (81.3)
Heavy (>50 eggs per 10 ml urine)	128 (17.8)	61 (16.9)	67 (18.7)
<i>S. mansoni</i>			
Light (1–99 eggs per gram stool)	87 (12.1)	44 (12.2)	43 (12.0)
Moderate (100–399 eggs per gram stool)	19 (2.65)	9 (2.50)	10 (2.79)
Heavy (>400 eggs per gram stool)	3 (0.42)	1 (0.28)	2 (0.56)
Clinical symptoms			
None	615 (85.7)	307 (85.28)	308 (86.03)
Abdominal pain	16 (2.23)	11 (3.06)	5 (1.40)
Blood in stool	14 (1.95)	7 (1.94)	7 (1.96)
Painful micturition	8 (1.11)	4 (1.11)	4 (1.12)
Gross hematuria	65 (9.05)	31 (8.61)	34 (9.50)
Indirect morbidity markers			
Presence of anemia (hemoglobin level <11.5 g dl <sup>-1</sup> )	229 (31.9)	112 (31.1)	117 (32.7)
Hemoglobin level (g dl <sup>-1</sup> ), median (IQR)	12.0 (11.3 to 12.7)	12.0 (11.3 to 12.8)	12.0 (11.3 to 12.7)
Presence of fecal occult blood (positive or trace)	166/682 (24.3)	79/338 (23.4)	87/344 (25.3)
Presence of microhematuria (1+ to 4+ on urine dipstick)	369/661 (55.8)	183/339 (54.0)	186/322 (57.8)
Presence of proteinuria (1+ to 3+ on urine dipstick)	294/661 (44.5)	146/339 (43.1)	148/322 (46.0)
Abdominal ultrasound findings			
Uni- and/or bilateral ureteral abnormalities (partial dilatation)	5/527 (1.0)	2/267 (0.8)	3/258 (1.2)
Focal/multifocal bladder abnormalities (wall irregularities or thickness, or masses >10 mm)	24/537 (4.5)	7/274 (2.6)	17/259 (6.6)
Liver abnormal patterns (C to F) <sup>b</sup>	9/531 (1.7)	4/271 (1.5)	5/260 (1.9)

<sup>a</sup>The intensity of infection for the microscopy results is categorized according to WHO recommendations<sup>9</sup>. <sup>b</sup>Patterns C to F correspond to ultrasound images indicating various degrees of liver fibrosis attributable to schistosomiasis. Note: all results are presented as n, or n/n (%), except otherwise mentioned; IQR denotes interquartile range.


praziquantel. No serious or severe AEs were reported during the three consecutive courses of artesunate–mefloquine.

At the interim assessment (week 24; Methods), the frequency of reported gross hematuria substantially decreased to <1% (2/679) in the study population (compared with 9% in the baseline assessment). Similarly, the proportion of participants with microhematuria sharply decreased from 55.8% at baseline to 7.3% at week 24, while the reduction of fecal occult blood positivity was less striking (from 24.3% at baseline to 18.0% at week 24). No statistical difference was observed between arms at week 24 in the frequency of schistosomiasis-related symptoms and laboratory abnormalities. The scheduled ultrasound assessments at weeks 24 and 48 could not take place because of the coronavirus disease 2019 (COVID-19) crisis.

No participant developed clinical malaria during the 1-year observation period and no cases of *P. falciparum* malaria infection was retrospectively detected in either arm. On a side note, at week 48 (end of study), the proportion of children positive for *Schistosoma* spp. by microscopy was above 80% in both study arms. All children enrolled in the trial received standard-care praziquantel treatment at that moment, according to the protocol.

### Sensitivity analysis

As shown in Supplementary Table 1, noninferiority of a single course of artesunate–mefloquine compared with a single dose of praziquantel was also consistently proven for all sensitivity analyses in the intention-to-treat population.



**Fig. 2 | Parasitological efficacy 4 weeks post treatment.** Efficacy results are shown as determined by microscopy for praziquantel (PZQ, white diamond) and artesunate–mefloquine (AM, black circle) in participants overall (pooled,  $n = 718$ ) and infected by *S. haematobium* (*Sh*,  $n = 713$ ) or *S. mansoni* (*Sm*,  $n = 109$ ). **a**, Estimated cure rates (proportion of participants without any *Schistosoma*

eggs at week 4) with 95% CI. **b**, Cure rate difference of artesunate–mefloquine compared with praziquantel with 95% CI. The dotted line represents the noninferiority margin for the difference in cure rates. **c**, Estimated egg reduction rates with 95% bootstrap CI. The striped line represents the efficacy threshold defined by WHO. AM, artesunate–mefloquine; PZQ, praziquantel.

**Table 2 | Frequency, severity, type and drug-relatedness of AE reports per study arm ('as treated' analysis)**

	PZQ up to week 4 (n=363)	AM up to week 4 (n=361)	AM up to week 16 (n=361)
Any AEs	14 (3.9; 2.3 to 6.4) <sup>a</sup>	29 (8.0; 5.6 to 11.3) <sup>a</sup>	41 (11.4; 8.5 to 15.0)
Any drug-related AEs	8 (2.2; 1.1 to 4.3) <sup>a</sup>	28 (7.8; 5.4 to 11.0) <sup>a</sup>	36 (10.0; 7.3 to 13.5)
Gastrointestinal disorders	8 (2.2)	26 (7.2)	31 (8.6)
Abdominal pain	5 (1.4)	15 (4.2)	18 (5.0)
Vomiting	4 (1.1)	12 (3.3)	14 (3.9)
Diarrhea	1 (0.3)	2 (0.6)	2 (0.6)
Odynophagia	–	–	1 (0.3)
Nervous system disorders	–	4 (1.1)	7 (1.9)
Headache	–	3 (0.8)	5 (1.4)
Vertigo	–	1 (0.3)	2 (0.6)
Other disorders			
Skin rash	–	1 (0.3)	1 (0.3)
Hematuria	–	1 (0.3)	1 (0.3)
Pyrexia	–	1 (0.3)	1 (0.3)
Cough	–	–	1 (0.3)
SAEs	–	–	–
Death	–	–	–
Confirmed malaria cases	–	–	–

Note 1: AM denotes artesunate–mefloquine; PZQ denotes praziquantel. Note 2: results are reported as  $n$  (%; 95% CI). All AEs ( $n = 41$ ) reported in the AM arm up to week 16 were classified as mild ( $n = 5$ ) or moderate ( $n = 36$ ). No grade 3 ('severe') AEs were reported. <sup>a</sup> $P$  values, determined with the Fischer's exact test, were 0.019 and  $<0.001$  for the comparisons between frequency of any AEs and any drug-related AEs, respectively, in the artesunate–mefloquine and praziquantel arms at week 4.

## Discussion

In this proof-of-concept, pragmatic, open-label, randomized, non-inferiority trial, we demonstrated that a 3-day course of artesunate–mefloquine at antimalarial dosage was noninferior to a standard single-dose of praziquantel, for the treatment of schistosomiasis in African schoolchildren. This observation was mainly driven by the effect on *S. haematobium* infection. The mean arithmetic egg reduction rates were, however, above the recommended threshold of 90% (ref. 9) for both *S. haematobium* and *S. mansoni* species. Drug-related AEs were more frequent in the artesunate–mefloquine arm compared

with the praziquantel arm, but they were all mild or moderate. An additional second and third courses of artesunate–mefloquine substantially increased the cure rate compared with a single course, with only a marginal increment of AEs. The frequency of schistosomiasis symptoms and abnormal morbidity markers 24 weeks after initial treatment decreased in similar proportions in both study arms.

This is an adequately powered trial that evaluated the parasitological and clinical efficacy of the antimalarial combination artesunate–mefloquine as an alternative to praziquantel for the treatment of schistosomiasis. This study also explored the incremental benefit, as well as cumulative toxicity, of repeated courses of artesunate–mefloquine. Apart from its large sample size, other strengths of this trial included its pragmatic school-based design, which is similar to the MDA reality, the rigorous parasitological evaluation by experienced microscopists blinded to treatment, the careful follow-up of potential mefloquine toxicity up to 1 month after each drug administration, and the molecular monitoring of malaria infection on dried blood spots in both study arms. There were also some limitations. For the efficacy outcome, cure rates were assessed by conventional microscopy, which is still the WHO established standard for diagnosis of schistosomiasis and assessment of treatment response<sup>9</sup>. However, microscopy is considered an insensitive method that tends to overestimate treatment efficacy. Concurrently with microscopic examinations, we therefore evaluated a set of highly sensitive antigen-based (that is, circulating cathodic and anodic antigens) and DNA-based detection assays as alternative tests of cure<sup>22</sup>; due to space limitations, comparative results on the performance of those diagnostics will be published elsewhere. The use of the egg reduction rate as measure for the efficacy outcome would have substantially inflated the required sample size, beyond the scope of a proof-of-concept trial. In addition, the study design did not allow to investigate the parasitic efficacy of a single course of artesunate–mefloquine beyond the week 4 assessment, although activity of mefloquine on juvenile worms may provide longer protection than praziquantel. For the safety analysis, the absence of praziquantel placebo comparison at weeks 6 and 12 might have overestimated the difference in occurrence of AEs between the two treatment arms. Also, this proof-of-concept trial, deliberately conducted in an area with low malaria endemicity to focus on schistosomiasis endpoints, did not provide insights on the potential benefits and risks of single and repeated artesunate–mefloquine administrations on malaria infection or on the potential emergence of resistance. Finally, the ultrasound assessments scheduled at the interim (week 24) and final (week 48) assessments could not take place because of the COVID-19 pandemic, during which schools were closed and large gatherings forbidden. The frequency of ultrasound abnormalities was, however, rather low at the initial assessment. The sampling of urine, stool and blood was able to be kept on schedule through door-to-door visits throughout the study period.

**Table 3 | Arithmetic and geometric egg reduction rates (ERRs in %) per *Schistosoma* species and study arm**

Species	Visit	Mean	Artesunate-mefloquine ERR (95% CI)	Praziquantel ERR (95% CI)	
<i>S. haematobium</i>	Week 4	Arithmetic	93.03 (89.22 to 95.19)	94.15 (90.74 to 95.67)	
		Geometric	85.56 (83.41 to 87.6)	85.53 (83.28 to 87.56)	
	Week 10	Arithmetic	95.53 (91.5 to 97.19)	91.51 (86.03 to 94.99)	
		Geometric	87.65 (85.85 to 89.33)	87.09 (84.86 to 88.98)	
	Week 16	Arithmetic	97.74 (95.01 to 98.85)	93.44 (87.57 to 96.41)	
		Geometric	89.05 (87.24 to 90.59)	87.97 (85.95 to 89.74)	
	Week 24	Arithmetic	98.6 (97.43 to 99.15)	94 (88.33 to 96.63)	
		Geometric	89.14 (87.24 to 90.59)	87.53 (85.45 to 89.37)	
	Week 48	Arithmetic	33.15 (12.55 to 49.63)	31.52 (10.41 to 49.28)	
		Geometric	45.61 (32.94 to 55.52)	36.5 (21.35 to 49.08)	
	<i>S. mansoni</i>	Week 4	Arithmetic	94.38 (82.25 to 98.79)	98.55 (93.93 to 100)
			Geometric	96.13 (93.93 to 97.4)	96.97 (95.76 to 97.78)
Week 10		Arithmetic	98.59 (95.11 to 99.75)	98.26 (85.21 to 100)	
		Geometric	96.85 (95.81 to 97.76)	96.96 (95.72 to 97.78)	
Week 16		Arithmetic	99.53 (96.58 to 100)	99.42 (96.44 to 100)	
		Geometric	97.33 (96.45 to 98.08)	97.14 (96.22 to 97.95)	
Week 24		Arithmetic	89.07 (69.25 to 97.61)	97.1 (91.35 to 99.06)	
		Geometric	95.79 (93.68 to 97.17)	96.46 (95.25 to 97.41)	
Week 48		Arithmetic	36.79 (-28.58 to 80.02)	52.34 (14.8 to 76.01)	
		Geometric	85.12 (73.57 to 91.65)	89.23 (80.67 to 93.85)	

Note: ERR denotes egg reduction rate (%). Determination of egg reduction rates is based on the WHO recommendations<sup>5</sup>. The number of eggs recorded in two urine (10 ml each) and two stool samples (two slides of 25 mg for each stool sample) were adjusted to number of eggs per 10 ml for urine samples and per gram for stool samples. The eggs in urine samples were calculated as: number of eggs per 10 ml = 10 × (number of eggs in sample 1 + number of eggs in sample 2) / (volume of sample 1 + volume of sample 2). The number of eggs in stool samples was calculated as: number of eggs per gram = 1,000 × (sum of eggs in all available slides) / (25 × number of slides). Of note, ectopic eggs were not taken into consideration in the calculations. The arithmetic egg reduction rate (ERR) was calculated using the following formula:  $ERR = 100 \times (1 - (\text{mean egg counts at visit } i) / (\text{mean egg counts at baseline}))$ . For the geometric ERR, the used formula was  $\exp(\text{mean}(\log(x+1)) - 1)$ , to include all samples with zero eggs, as described in Olliaro<sup>38</sup>. The CIs for the ERR were calculated using a bootstrap resampling method (with replacement) over 2,000 replicates and expressed as adjusted bootstrap 2.5th and 97.5th percentiles.


The clinical efficacy of artemisinin derivatives on schistosomiasis has been found inferior to that of praziquantel<sup>18,27</sup>, as their activity is mainly restricted to the juvenile worms. In addition, the use of artemisinin derivatives in monotherapy as antischistosomal agents cannot be envisaged in the large areas of sub-Saharan Africa where *P. falciparum* is co-endemic, given the risk of malaria resistance to

this key compound. Mefloquine is an antimalarial drug with activity against both juvenile and adult *Schistosoma* worms, but the clinical evidence of efficacy is very limited<sup>16,19,20</sup>. The evaluation of the artesunate-mefloquine combination has provided equivocal results in two small exploratory trials, so far<sup>16,20</sup>. The current trial demonstrates substantial antiparasitic activity of artesunate-mefloquine, with clinical benefit on schistosomiasis-related symptoms and morbidity, and the incremental effect of successive treatment courses. Additionally, its safety profile is confirmed, even in repeated administration, at least in the pediatric population<sup>21,28,29</sup>. Therefore, the important potential of artesunate-mefloquine as repurposed antischistosomal drug is highlighted, with the key advantage that it is a cheap and immediately available treatment. The slightly lower tolerance and need of 3-day administration would, however, position it as second-line treatment, in case of intolerance or decreased susceptibility to praziquantel, pending future feasibility and acceptability studies. Acute schistosomiasis in nonimmune travelers could be another clinical scenario where the artesunate-mefloquine combination, with its activity on juvenile worms, would be worth being evaluated against praziquantel.

Moreover, the concomitant antimalarial and antischistosomal activity of artesunate-mefloquine opens exciting research perspectives in coinfecting patients and in co-endemic areas<sup>30</sup>. The dual benefit for coinfecting patients appears quite obvious, but the simultaneous diagnosis of both infections is probably infrequent in first-line health facilities. However, artesunate-mefloquine could be studied as the preferred ACT in any child presenting with clinical malaria in regions moderately or highly prevalent for schistosomiasis. In a larger perspective, as transmission of both malaria and schistosomiasis peaks during the rainy season in Africa, it would also be interesting to explore the dual protective effect of seasonal administration of artesunate-mefloquine at the community level, by analogy with the seasonal preventive chemotherapies recommended by the WHO for malaria control<sup>31-34</sup>. Since repeated courses are acceptably safe and provide cumulative efficacy on schistosomiasis, it would be worth evaluating different schedules and timing of artesunate-mefloquine as seasonal chemoprevention against both malaria<sup>31</sup> and schistosomiasis in school-aged children. In a next step, research into artesunate-mefloquine as an alternative seasonal (malaria) chemoprevention in children <5 years could also be considered, as this age group is also particularly affected by both conditions.

Perennial or seasonal intermittent preventive treatment in school-aged children is conditionally recommended by the WHO in malaria-endemic settings with moderate to high transmission, preferably with regimens not used locally as first or second-line malaria treatment<sup>31</sup>. Artesunate-mefloquine could be a good investigational candidate for seasonal intermittent preventive treatment in children of different age groups, in settings where prevalence of both malaria and schistosomiasis is moderate or high. However, the emergence of artemisinin resistance in the past few years in East Africa<sup>35</sup> has increased legitimate concerns about the use of ACT-based preventive chemotherapies. Although there is no evidence that such interventions promote clinical resistance<sup>36</sup>, adequate molecular monitoring should be integrated into each new trial and routinely established wherever implementation of such strategy is being considered. Next-generation sequencing tools such as deep amplicon sequencing, capable of targeting multiple markers in a single assay, are gradually being deployed to support the surveillance activities of malaria control programs<sup>37</sup>.

In conclusion, the combination artesunate-mefloquine at antimalarial dosage is safe and its efficacy against schistosomiasis is noninferior to that of standard-care praziquantel, at least for *S. haematobium* infection. If similar results are reproduced in other epidemiological settings, especially where *S. mansoni* is more prevalent, or in other demographics, such as malaria-coinfecting patients, more advanced schistosomiasis cases or pre-school-aged children, it could become one of the much-needed alternative drugs for individualized treatments.



**Fig. 3 | Parasitological efficacy of repeated administrations of artesunate–mefloquine. a**, Cure rates (proportion of participants without any *Schistosoma* eggs) with 95% CI are shown as determined by microscopy in the praziquantel (PZQ, white diamond) and artesunate–mefloquine (AM, black circle) arms

in participants infected with any *Schistosoma* species ( $n = 718$ ). **b**, Cure rate difference with 95% CI of repeated administrations of artesunate–mefloquine (as assessed at weeks 10, 16 and 24 post-initial treatment), compared with week 4 assessment. Detailed numbers are available in Supplementary Table 2.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02719-4>.

## References

- Abajobir, A. A. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* **390**, 1211–1259 (2017).
- Colley, D. G., Bustinduy, A. L., Secor, W. E. & King, C. H. Human schistosomiasis. *Lancet* **383**, 2253–2264 (2014).
- McManus, D. P. et al. Schistosomiasis. *Nat. Rev. Dis. Primers* **4**, 13 (2018).
- Bergquist, R., Utzinger, J. & Keiser, J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? *Infect. Dis. Poverty* **6**, 1–10 (2017).
- Lai, Y.-S. et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. *Lancet Infect. Dis.* **15**, 927–940 (2015).
- Lo, N. C. et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. *Lancet Infect. Dis.* **22**, e327–e335 (2022).
- Zwang, J. & Olliaro, P. L. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis—a meta-analysis of comparative and non-comparative clinical trials. *PLoS Negl. Trop. Dis.* **8**, e3286 (2014).
- Zwang, J. & Olliaro, P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. *Parasit. Vectors* **10**, 47 (2017).
- WHO. *Assessing the Efficacy of Anthelmintic Drugs against Schistosomiasis and Soil-Transmitted Helminthiasis* 1–29 (WHO, 2013).
- Wu, W., Wang, W. & Huang, Y. X. New insight into praziquantel against various developmental stages of schistosomes. *Parasitol. Res.* **109**, 1501–1507 (2011).
- Crellen, T. et al. Reduced efficacy of praziquantel against *Schistosoma mansoni* is associated with multiple rounds of mass drug administration. *Clin. Infect. Dis.* **63**, 1151–1159 (2016).
- Gardner, J. M. F., Mansour, N. R., Bell, A. S., Helmbly, H. & Bickle, Q. The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult schistosoma species. *PLoS Negl. Trop. Dis.* **15**, e0009490 (2021).
- Saeed, M. E. M., Krishna, S., Johannes, H., Kremsner, P. G. & Efferth, T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. *Pharmacol. Res.* **110**, 216–226 (2016).
- Abou-shady, O. M. Therapeutic effect of mefloquine on *Schistosoma mansoni* in experimental infection in mice. *J. Parasit. Dis.* **40**, 259–267 (2016).
- Utzinger, J., Tanner, M. & Keiser, J. ACTs for schistosomiasis: do they act? *Lancet Infect. Dis.* **10**, 579–581 (2010).
- Keiser, J. et al. Efficacy and safety of mefloquine, artesunate, mefloquine–artesunate, and praziquantel against *Schistosoma haematobium*: randomized, exploratory open-label trial. *Clin. Infect. Dis.* **50**, 1205–1213 (2010).
- Keiser, J. & Utzinger, J. Antimalarials in the treatment of schistosomiasis. *Curr. Pharm. Des.* **18**, 3531–3538 (2012).
- Perez del Villar, L., Burguillo, F. J., Lo, J., Muro, A. & Pe, L. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. *PLoS ONE* **7**, e45867 (2012).
- Basra, A. et al. Efficacy of mefloquine intermittent preventive treatment in pregnancy against schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. *Clin. Infect. Dis.* **56**, 68–75 (2013).
- Keiser, J. et al. Praziquantel, mefloquine–praziquantel, and mefloquine–artesunate–praziquantel against *Schistosoma haematobium*: a randomized, exploratory, open-label trial. *PLoS Negl. Trop. Dis.* **8**, e2975 (2014).
- Sirima, S. B. et al. Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated *Plasmodium falciparum* malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. *Lancet Infect. Dis.* **16**, 1123–1133 (2016).
- Roucher, C. et al. Evaluation of artesunate–mefloquine as a novel alternative treatment for schistosomiasis in African children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial. *BMJ Open* **11**, e047147 (2021).
- Léger, E. et al. Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system. *Lancet Planet Health* **4**, e330–e342 (2020).
- Bulletin Epidémiologique Annuel du Paludisme au Sénégal 2021 (Programme de Contrôle du Paludisme, 2022).
- Karagiannis-Voules, D. A. et al. Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis. *Lancet Infect. Dis.* **15**, 74–84 (2015).

26. Sartorius, B. et al. Prevalence and intensity of soil-transmitted helminth infections of children in sub-Saharan Africa, 2000–18: a geospatial analysis. *Lancet Glob. Health* **9**, e52–e60 (2021).
27. Liu, R., Dong, H., Guo, Y., Zhao, Q. & Jiang, M. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and. *Parasit. Vectors* **4**, 201 (2011).
28. Schlagenhauf, P. et al. Use of mefloquine in children—a review of dosage, pharmacokinetics and tolerability data. *Malar. J.* **10**, 292 (2011).
29. Lee, S. J., Ter Kuile, F. O., Price, R. N., Luxemburger, C. & Nosten, F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19, 850 individual patients. *PLoS ONE* **12**, 1–16 (2017).
30. Degarege, A. et al. *Plasmodium falciparum* infection status among children with schistosoma in sub-Saharan Africa: a systematic review and meta-analysis. *PLoS Negl. Trop. Dis.* **10**, 1–18 (2016).
31. *WHO Guidelines for Malaria. 14 March 2023* (World Health Organization, 2023)
32. Cohee, L. M. et al. Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. *Lancet Glob. Health* **8**, e1499–e1511 (2020).
33. Cissé, B. et al. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. *PLoS Med.* **13**, 1–18 (2016).
34. Cairns, M. et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case–control studies in 5 countries. *PLoS Med.* **18**, e1003727 (2021).
35. Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. *N. Engl. J. Med.* **385**, 1163–1171 (2021).
36. Plowe, C. V. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. *Malar. J.* **21**, 104 (2022).
37. Kattenberg, J. H. et al. Malaria molecular surveillance in the peruvian amazon with a novel highly multiplexed *Plasmodium falciparum* AmpliSeq assay. *Microbiol. Spectr.* **11**, e0096022 (2023).
38. Olliaro, P. L. et al. Toward measuring schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. *PLoS Negl. Trop. Dis.* **9**, e0003821 (2015).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

**Emmanuel Bottieau**<sup>1,8</sup>✉, **Moustapha Mbow**<sup>2,3,8</sup>, **Isabel Brosius**<sup>1</sup>, **Clémentine Roucher**<sup>4</sup>, **Cheikh Tidiane Gueye**<sup>2</sup>, **Ousmane Thiam Mbodj**<sup>2</sup>, **Babacar Thiendella Faye**<sup>2</sup>, **Annelies De Hondt**<sup>1</sup>, **Bart Smekens**<sup>1</sup>, **Diana Arango**<sup>1</sup>, **Christophe Burm**<sup>1</sup>, **Achilleas Tsoumanis**<sup>1</sup>, **Linda Paredis**<sup>4</sup>, **Yven Van Herreweghe**<sup>1</sup>, **Idzi Potters**<sup>1</sup>, **Joachim Richter**<sup>5</sup>, **Anna Rosanas-Urgell**<sup>4</sup>, **Badara Cissé**<sup>2</sup>, **Souleymane Mboup**<sup>2</sup> & **Katja Polman**<sup>6,7</sup>

<sup>1</sup>Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. <sup>2</sup>Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal. <sup>3</sup>Department of Immunology, Cheikh Anta Diop University, Dakar, Senegal. <sup>4</sup>Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. <sup>5</sup>Institute of Tropical Medicine and International Health, Charité Universitätsmedizin, Berlin, Germany. <sup>6</sup>Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. <sup>7</sup>Department of Health Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. <sup>8</sup>These authors contributed equally: Emmanuel Bottieau, Moustapha Mbow. ✉e-mail: [ebottieau@itg.be](mailto:ebottieau@itg.be)



## Methods

### Study design and setting

This was a proof-of-concept, pragmatic (school-based), open-label, phase 2b, randomized, active control, noninferiority trial, comparing the investigational treatment (3-day course of artesunate–mefloquine combination at antimalarial dosage) to the standard of care (standard 40 mg kg<sup>-1</sup> single dose of praziquantel) for the treatment of schistosomiasis. The trial took place in the primary schools of six villages (Yetty-Yone, Nder, Pakh, Gnith, Colona and Ronkh), selected on the basis of a parasitological survey before the trial, in the Richard Toll District, located in the northern Saint-Louis Region of Senegal. This area is characterized by a high co-endemicity of both *S. haematobium* and *S. mansoni* species, and a very low malaria incidence.

### Participants

Participants for this trial were recruited among primary school-aged children (6–14 years old) from the six selected villages. The purpose and methodology of the trial were presented in detail to the community leaders, school directors, teaching staff and children's parents. Written informed consent for schistosomiasis screening and trial participation upon positivity was asked by experienced study nurses from the children's parents or legal guardians. Participants' gender was assessed by parental reporting (for the younger children) and/or by self-reporting (for the older ones). Oral assent was also obtained from the children.

During the initial screening survey in the schools of the selected villages, all consenting children provided one urine and one stool sample for parasitological analyses in the laboratory of the Richard-Toll Hospital. Children fulfilling the inclusion criteria during this screening (that is, signed informed consent and presence of at least one egg of *S. haematobium* or *S. mansoni* in any of the urine or stool samples) were invited for a baseline assessment before enrollment in the trial.

Baseline assessment included parasitological confirmation and quantification of *Schistosoma* infection (both with microscopy and novel diagnostics, see below), as well as a medical and laboratory evaluation. Detailed descriptions were published elsewhere<sup>22</sup>. For the parasitological baseline assessment, two urine and two stool samples were collected on consecutive days. From each patient, 10 ml of each urine sample was filtered with the standard filtration technique, while a total of 50 mg (2 × 25 mg per slide) from each of both stool samples were examined using the duplicate Kato-Katz method. The resulting slides were examined microscopically (AML120EB biological microscope, a.m.l. sprl). Each of the two study microscopists read half of the urine and stool slides, and 10% of the slides were re-read by the other one every day. In case of discordant results (this occurred in less than 2% of the revised slides), those assessed by the most experienced microscopist were entered in the database. In accordance with the SchisoSAM protocol<sup>22</sup>, in parallel to conventional microscopy, DNA- and antigen-based assays (both the point-of-care circulating cathodic antigen and circulating anodic antigen) were also systematically run either in the study hospital or in reference laboratories (methods and results to be reported in a second manuscript). The medical evaluation was performed in the study schools and included the measurement of body weight and height, a clinical examination focused on schistosomiasis-related complications, the determination of the hemoglobin level via a finger prick (with HemoCue Hb 301, HemoCue), and an abdominal ultrasound exploration of urinary or hepatic abnormalities<sup>39</sup> by an experienced radiologist with a portable machine (Samsung Medison SonoAce R3). The laboratory evaluation included the search for microhematuria in urine (with the heme reagent dipstick test Medi-Test Combi-5, Macherey-Nagel) and fecal occult blood in stool samples (with Mission test, Acon Laboratories) in the hospital laboratory, as indirect markers of schistosomiasis morbidity<sup>40</sup>. Informed consent was confirmed and validated by the study physician after a thorough check for exclusion criteria. The exclusion criteria were: (1) past or present diagnosis of epilepsy or psychiatric illness; (2) history of hypersensitivity to one of

the study drugs (praziquantel or artesunate–mefloquine); (3) chronic medication for any reason; (4) exposure to praziquantel or any ACT within 3 months before inclusion; (5) current febrile illness or clinical malaria at the time of inclusion; (6) any severe underlying illness based on clinical judgment (for example, severe malnutrition), severe anemia defined by an hemoglobin level below 7 g dl<sup>-1</sup>, or severe chronic schistosomiasis, as assessed by clinical and/or ultrasound examination (7) planned travel for more than 1 month within the first 4 months after enrollment. Infected children not eligible for the study because of the presence of any exclusion criteria were administered a standard single-dose of praziquantel as standard of care, and referred to medical attention if necessary.

### Randomization and masking

A block randomization schedule, stratified by the two *Schistosoma* species, was prepared by the sponsor biostatistician, using SAS v9.4 (SAS Institute). In case of coinfection, patients were stratified within the *S. mansoni* group, as numbers were expected to be lower for this species. The individual randomization numbers and corresponding treatment arm were stored in sealed opaque envelopes and opened by the study physician for each child at enrollment. The participants and the clinical team were not blinded to treatment and clinical evolution, but the laboratory technicians and microscopists were.

### Procedures

Assenting eligible children were randomly allocated in a 1:1 ratio to standard of care (praziquantel) or the investigational treatment (artesunate–mefloquine). Standard of care consisted of oral administration of a single dose of praziquantel at the WHO-recommended dosage of 40 mg kg<sup>-1</sup>. The investigational drug combination was given orally at the antimalarial dosage of 4 mg kg<sup>-1</sup> per day of artesunate and 8 mg kg<sup>-1</sup> per day of mefloquine daily over three consecutive days (total dose of 12 mg kg<sup>-1</sup> artesunate + 24 mg kg<sup>-1</sup> mefloquine). Both praziquantel and artesunate–mefloquine were donated by the Indian manufacturer Cipla (prequalification WHO reference number: artesunate–mefloquine 25/50 MA078, artesunate–mefloquine 100/200 MA079, praziquantel NT003), which had not been involved in the development of this study protocol. After calculation of the adequate weight-based dosage, ingestion of both standard-of-care and investigational treatment was directly observed by the study staff in the schools, after which all children received a light meal. Each participant was monitored during 2 h for any adverse reactions. If a child vomited within half an hour, the full dose was repeated; if vomiting occurred after 30 min, but within 2 h, half of the dose was re-administered. If repeating the dose resulted in recurrent vomiting, treatment was discontinued.

In the artesunate–mefloquine arm, a second and third 3-day course of artesunate–mefloquine were administered under medical supervision 6 and 12 weeks after the initial treatment, respectively. A 6-week interval between each artesunate–mefloquine administration was chosen to reduce the risk of cumulative mefloquine-related neuropsychiatric AEs. Safety visits to the sites by physicians took place every day during the 3-day period of artesunate–mefloquine administration. Participants were also visited by study nurses one week after each drug administration to capture any additional AE. Medical, laboratory and parasitological follow-up assessments took place for all participants in both arms at week 4, 10, 16 (corresponding to 4 weeks after each artesunate–mefloquine course), as well as week 24 after initial treatment (interim assessment) and week 48 (final/end of study assessment). The follow-up sampling was organized within the primary schools in close collaboration with community health workers and teachers. All samples were cryopreserved to perform additional molecular and antigenic diagnostic investigations as detailed in the published study protocol<sup>22</sup>.

For the molecular diagnosis of malaria by quantitative polymerase chain reaction (qPCR), filter papers with dried blood samples (finger prick) from peripheral blood were punched and three circles of

5 mm in diameter was used for DNA extraction with QIAamp 96 DNA blood kit (Qiagen) in the research laboratory of the Unit of Malariaology (ITM). Extracted DNA was eluted in 150 µl of water. Five microliters of DNA were used for qPCR analysis targeting *P. falciparum* var gene acidic terminal sequence (varATS, ~59 copies per genome) as previously described<sup>41</sup>. The limit of detection in our laboratory was 0.1 parasite µl<sup>-1</sup>. In case of positive *P. falciparum* samples, and to identify genetic variants associated with resistance, it was planned to perform a highly multiplexed deep sequencing assay (PfAmpliSeq), which allows high-accuracy sequencing with higher coverage and lower cost than whole-genome sequencing<sup>42</sup>.

All participants, whether or not they completed the study, were offered praziquantel as standard of care at the final study visit (week 48 post-inclusion).

## Outcomes

The primary outcome was the cure rate as assessed by microscopy of urine and stool 4 weeks after treatment. Cure rate was defined as the proportion of egg-positive children at baseline, who became egg-negative 4 weeks after treatment in all collected samples. The co-primary outcome was the frequency and type of AEs and serious AEs (SAEs) in both arms. Any clinical sign or symptom was reported as an AE if it occurred or worsened after the start of study treatment. AEs were assessed in both arms by the study doctors during three days after treatment administration, and recorded by the study nurses and assisting community workers at weeks 1 and 4 post-treatment. Assessment of AEs was repeated following the same schedule in the artesunate–mefloquine arm only after the second and third courses. Nurses of the health centers in the six villages were also involved in the trial follow-up and instructed to contact the study physicians in case of any incidental problem occurring to a study participant between the visits of the study team.

Secondary outcomes included (1) the cure rates by *Schistosoma* species and the arithmetic and geometric egg reduction rates in both arms, at week 4 post-treatment, (2) the cumulative cure rates in the artesunate–mefloquine arm 10, 16 and 24 weeks after the initial treatment, (3) the cumulative frequency and type of AEs after each additional artesunate–mefloquine course, and (4) the number of episodes of clinical malaria among participants as captured by the regional surveillance system in place, as well as the prevalence of *P. falciparum* malaria infection in both study arms, as retrospectively assessed by quantitative polymerase chain reaction on dried blood spot samples. Of note, egg reduction rate was not retained as primary endpoint, because the sample size necessary to demonstrate noninferiority would have been much higher, beyond reach of a proof-of-concept trial.

Clinical, ultrasound, laboratory and parasitological data at baseline and during follow-up assessments were entered into Research Electronic Data Capture (REDCap, v8.10.4), an International Council for Harmonization–Good Clinical Practice compliant data capture system. The data system included password protection and internal validation checks to identify data that appeared inconsistent, incomplete or inaccurate.

## Statistical analysis

The sample size calculation was based on the hypothesis that the cure rate (as assessed by microscopy) after the first course of artesunate–mefloquine (that is, primary outcome) was noninferior to that of praziquantel with a power of 80%. Compared with the usual cure rate with standard single-dose praziquantel (estimated at 75% (95% CI 63 to 81)), a maximum difference of 10% was considered as an acceptable margin for noninferiority of artesunate–mefloquine. This large margin was clinically chosen considering the concomitant beneficial impact on malaria infection that could be expected with artesunate–mefloquine in the large co-endemic areas co-endemic settings. It was agreed upon among clinicians that this assumed additional benefit on malaria could

justify a treatment with a slightly lower efficacy on schistosomiasis (compared with praziquantel). To confirm noninferiority at the chosen cutoff, the required sample size was 300 schoolchildren per arm, but to account for a 20% loss to follow-up, the total number of children to be randomized was 720 (360 per arm). For the efficacy analysis, both an intention-to-treat and a per-protocol approach were adopted, with the per-protocol analysis being used for the primary outcome, as recommended for noninferiority studies in the Consort statement on noninferiority trials (CONSORT–Reporting of Non-inferiority and Equivalence Randomized Trials: [www.consort-statement.org](http://www.consort-statement.org)) and International Council for Harmonization guidelines. The primary hypothesis for noninferiority was assessed by calculating the two-sided 95% Wilson CI for the difference in cure rates between arms (artesunate–mefloquine and praziquantel). If the resulting 95% CI was entirely above –10%, then noninferiority of the artesunate–mefloquine treatment could be concluded. For the safety evaluation, all participants who received at least one dose of study medication were included in the ‘as treated’ analysis. Safety events were described using patient counts and percentages with 95% CIs, and comparisons between arms (at week 4 post-treatment) and between artesunate–mefloquine courses were performed using Fisher’s exact test.

Statistical analysis were performed with R v4.2.2. No specific gender-based analysis was performed, as it was not considered as relevant for the trial on drug efficacy and safety.

## Ethics and inclusion statement

This project was designed through a longstanding partnership between the Institute of Tropical Medicine (ITM) in Antwerp, Belgium and the ‘Institut de Recherche en Santé de Surveillance Épidémiologique et de Formation’ (IRESSEF) in Dakar, Senegal. Since the early 2000s, multiple epidemiological and diagnostic studies on schistosomiasis have been conducted in connection with this scientific collaboration, especially in the Richard-Toll District, Saint-Louis Region of Senegal, as documented by a number of joint publications<sup>43–50</sup>. During the preparation of the project, other key players such as the National Control Programs (for Neglected Tropical Diseases and for Malaria) were consulted and informed about the study objectives, and their respective feedback was integrated in the final protocol. Roles and responsibilities were shared between Senegalese and Belgian researchers, with co-principal investigators and co-primary authors of each nationality.

The District of Richard-Toll was selected as trial site, for the epidemiological reasons explained in this manuscript, but also because an experienced field team (nurses, microscopists and laboratory technicians) has been present for about 20 years. This team, deeply rooted in the local communities, has carried out numerous schistosomiasis research activities over the years, often door to door, and has gained the full trust of village leaders and communities. As described in the published protocol<sup>22</sup>, the preparation of this community trial consisted of repeated dedicated visits to the population (parents, children, school principals, teaching staff and community leaders) of potentially eligible villages, to explain the objectives and methods, as well as the expected benefits and risks. Sufficient time was spent on questions and answers about the project during successive meetings. The engagement of the study team was instrumental in limiting the number of participants lost to follow-up and in ensuring field activities continued during the COVID-19 crisis.

All IRESSEF, ITM and local investigators collaborated on data ownership and authorship of publications related to the project. All analyses and results will be shared to national, regional and local co-investigators and stakeholders during a closing visit for this trial in Dakar and Richard-Toll.

## Ethics approval

The trial was approved by the Institutional Review Board of the Institute of Tropical Medicine (on 30 January 2019, Ref. 1269/18) and the

Ethics Committee of the University of Antwerp, (on 21 January 2019, Ref. 19/02/005), in Antwerp, Belgium, as well as by the National Ethics Council for Research in Health (CNERS) in Dakar, Senegal (on 24 April 2019, Ref. SEN19/08).

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Open access information on the SchistoSAM trial such as the trial protocol, informed consent form and statistical analysis plan is published in the Clinicaltrials.gov registry with code [NCT03893097](https://clinicaltrials.gov/ct2/show/study/NCT03893097). These documents, as well as the REDCap codebook and statistical codes have been publicly available in the Zenodo repository (at <https://zenodo.org/records/10089112>; <https://doi.org/10.5281/zenodo.10089112>). Individual participant data have been deposited in Zenodo also, but is subject to controlled access due to privacy reasons and the European data protection legislation and can only be accessed after review and approval by the Data Access Committee (DAC) of the Institute of Tropical Medicine (full information at <https://www.itg.be/en/research/data-sharing-and-open-access>). A request can be made by submitting a data access request form to [ITMresearchdataaccess@itg.be](mailto:ITMresearchdataaccess@itg.be). The DAC will review the suitability of the data for the secondary research proposal, the amount of (indirect) identifiers needed and the possibility of sufficient anonymization, as well as the scientific value and ethical aspects, in collaboration with the principal investigators. An answer to the requests will be formulated within a month. The DAC has the expertise to anonymize the data (in line also with the European General Data Protection Regulation) and will draw up a data sharing agreement before data can be shared.

### Code availability

In line with the previous statement, statistical codes have been made available in the Zenodo repository (see above for identifiers).

### References

39. Hatz, C. The use of ultrasound in schistosomiasis. *Adv. Parasitol.* **48**, 225–284 (2001).
40. Webster, J. P., Koukounari, A., Lamberton, P. H. L., Stothard, J. R. & Fenwick, A. Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. *Parasitology* **136**, 1789–1799 (2009).
41. Hofmann, N. et al. Ultra-sensitive detection of *Plasmodium falciparum* by amplification of multi-copy subtelomeric targets. *PLoS Med.* **12**, e1001788 (2015).
42. Kattenberg, J. H. et al. Molecular surveillance of malaria using the PF AmpliSeq custom assay for plasmodium falciparum parasites from dried blood spot DNA isolates from Peru. *Bio Protoc.* **13**, e4621 (2023).
43. Gryseels, B. et al. Are poor responses to praziquantel for the treatment of *Schistosoma mansoni* infections in Senegal due to resistance? An overview of the evidence. *Trop. Med Int. Health* **6**, 864–873 (2001).
44. Meurs, L. et al. Epidemiology of mixed *Schistosoma mansoni* and *Schistosoma haematobium* infections in northern Senegal. *Int. J. Parasitol.* **42**, 305–311 (2012).
45. Meurs, L. et al. Micro-geographical heterogeneity in *Schistosoma mansoni* and *S. haematobium* infection and morbidity in a co-endemic community in Northern Senegal. *PLoS Negl. Trop. Dis.* **26**, e2608 (2013).
46. Mbow, M. et al. T-helper 17 cells are associated with pathology in human schistosomiasis. *J. Infect. Dis.* **207**, 186–195 (2013).
47. Mbow, M. et al. Changes in immunological profile as a function of urbanization and lifestyle. *Immunology* **143**, 569–577 (2014).

48. Meurs, L. et al. Is PCR the next reference standard for the diagnosis of schistosoma in stool? A comparison with microscopy in Senegal and Kenya. *PLoS Negl. Trop. Dis.* **28**, e0003959 (2015).
49. Huyse, T. et al. Evolutionary epidemiology of schistosomiasis: linking parasite genetics with disease phenotype in humans. *Int. J. Parasitol.* **48**, 107–115 (2018).
50. Boon, N. A. M. et al. No barrier breakdown between human and cattle schistosome species in the Senegal River Basin in the face of hybridisation. *Int. J. Parasitol.* **49**, 1039–1048 (2019).

### Acknowledgements

This study was supported by the Flemish Ministry of Economy, Sciences and Innovation (EWI), which was granted in the framework of the Structural Research Funding of ITM (SOFI), a competitive internal grant of the Institute of Tropical Medicine (grant number DIR/av/2018/90; obtained by E.B. and K.P.). The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. We are grateful to the Cipla company for providing both study drugs at no cost. The company had no role in study design, data collection, data analysis, data interpretation or writing of the report. We also thank all nurses, community health workers, laboratory technicians, school teachers and directors and community leaders, without whom this trial would not have been possible. We want to especially highlight the tremendous efforts of the field staff, who maintained all follow-up samplings on schedule through door-to-door visits during the COVID-19 pandemic. We are also grateful to the members of the Data Safety Monitoring Board (DSMB) for their critical and regular review of the trial data. The DSMB was composed of (1) D. Van Der Linden, pediatrician specialized in Infectious Diseases, Catholic University of Louvain, Belgium, (2) F. Gobbi, Sacro Cuore don Calabria Hospital, Negrar, Italy, and (3) T. Pistone, University Hospital of Bordeaux, France, both internists specialized in Infectious and Tropical Diseases.

### Author contributions

E.B., M.M., Y.V.H., B.C., S.M. and K.P. conceived, designed and planned this study. E.B., M.M., I.B., C.R., C.T.G., O.T.M., B.T.F., A.D.H., B.S., D.A., C.B., L.P., I.P., J.R., B.C. and K.P. collected and acquired the data. J.R. performed all ultrasound examinations, with support of M.M. and I.B. A.R. performed the malaria molecular analyses. E.B., A.T. and D.A. revised all data. E.B., M.M., I.B., A.T., D.A. and K.P. analyzed the data. E.B., M.M., I.B., C.R., A.T., D.A., L.P., I.P. and K.P. interpreted the data. E.B., M.M., I.B., A.T. and K.P. drafted the paper. All authors critically reviewed the paper. E.B., M.M., I.B., A.T. and K.P. revised the final paper. All authors had access to all the data in the study. All authors were responsible for the decision to submit for publication.

### Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02719-4>.

**Correspondence and requests for materials** should be addressed to Emmanuel Bottieau.

**Peer review information** *Nature Medicine* thanks Jennifer Friedman, Maurizio Rainisio and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling editor: Sonia Muliyil, in collaboration with the *Nature Medicine* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a | Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

A set of study-related documents such as the study protocol, statistical analysis plan, informed consent form, CONSORT checklist, ... have been made publicly available in Zenodo repository (at <https://zenodo.org/records/10082977>), with the following DOI 10.5281/zenodo.10082977). De-identified individual participant data and a data dictionary defining each field in the set can be made available to others after publication, with a controlled access (for pre-approval of a written request to

the Data Access Committee of the Institute of Tropical Medicine, Antwerp (mail to at . The request will be evaluated for suitability and scientific value of the secondary research by this Data Access Committee, in collaboration with the principal investigators. A data sharing agreement will be needed.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	Only gender was collected in this study, based .on parents' reporting or self-reporting (depending on children's age)
Population characteristics	Primary school-aged children (6-14 years old) from six selected villages in Senegal, who tested positive for schistosomiasis
Recruitment	The selection of the six endemic villages was based on a parasitological survey prior to the trial. The purpose and methods of the trial were presented in detail to the community leaders, school directors, teaching staff and children's parents. Written informed consent for schistosomiasis screening and trial participation upon positivity, was asked from the children's parents or legal guardians. Oral assent was also obtained from the children. Enrollment to the trial was offered to the children found with Schistosoma eggs by microscopic examination of urine and/or stool. found e found positive. The main bias was that only school-attending children were recruited. Other children in the communities (not attending school) might have had higher intensities of infection, and possibly lower response to the evaluated drugs.
Ethics oversight	The trial was approved by the Institutional Review Board of the Institute of Tropical Medicine (on 30 January 2019, Ref. 1269/18) and the Ethics Committee of the University of Antwerp, (on 21 January 2019, Ref. 19/02/005), in Antwerp, Belgium, as well as by the National Ethics Council for Research in Health (CNERS) in Dakar, Senegal (on 24 April 2019, Ref. SEN19/08).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The sample size was calculated by simulation, for the non-inferiority of AM versus PZQ. A cure rate of 75% was assumed for both treatments with a non-inferiority margin of 10%. To ensure a power of 80% a sample size of 300 participants per arm would be needed. The sample size was corrected for an expected 20% attrition, thus increasing the final sample size to 360 participants per arm.
Data exclusions	Participants who were found negative for schistosomiasis were excluded from all analyses and were not randomized according to the study exclusion criteria. Participants with no available samples at baseline were also excluded. A further 5 participants were excluded from all analyses due to suspicion of misidentification. For efficacy analyses, both an intention to treat and per-protocol analyses populations were defined. In the per-protocol population, all participants that did not follow the study procedures according to the protocol (exclusion criteria, erroneous treatment, missed treatment, no stool/urine samples, dosage miscalculation, out-of-window visit) were excluded. The per-protocol population was the primary analysis population as recommended for non-inferiority trials.
Replication	No explicit measures for replication were taken in this study, considering the unique setting and timing the trial was set. However, a detailed description of sampling, laboratory procedures and statistical analyses would allow a similar experiment to be conducted.
Randomization	Blocked randomization, stratified by Schistosoma species was used to randomize participants into the two treatment arms. Opaque sealed envelopes were used to ensure that the randomization process will be respected
Blinding	This was an open-label clinical trial, thus both participants and investigators were unblinded to the allocated treatment. Microscopists who assessed the parasitological efficacy (urine/stool) were blinded to treatment arms.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

## Methods

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	NCT03893097
Study protocol	DOI: 10.1136/bmjopen-2020-047147
Data collection	Clinical data were collected via the REDCap tool directly in the study sites (primary schools of the selected villages in Richard Toll district, Senegal. Results of the laboratory analyses performed in Richard Toll hospital, in Dakar (IRESSEF) and in Antwerp (ITM) were also collected via REDCap.
Outcomes	<p>The primary objectives of this noninferiority trial were to compare the cure rate (as assessed by measurement of egg excretion in urine/stool by microscopy) and safety (frequency and type of adverse events) of a three-day course of the artesunate-mefloquine combination at antimalarial dosage versus the standard-care single-dose praziquantel for the treatment of schistosomiasis in African primary school-aged children. The efficacy outcome (cure rate) was measured by the proportion of trial participants without any Schistosoma eggs at Week 4 (assessed by urine filtration and duplicate Kato-Katz). The safety outcome was measured by the proportion of participants reporting any adverse events during and after the study drug administration during field visits). Relatedness with the drug was determined by the local clinical investigators.</p> <p>The secondary objectives were (1) to determine the egg reduction rates by Schistosoma species (as assessed by comparing the egg concentrations for each species by microscopy in urine and stool before and at Week 4 after treatment); (2) to assess the cumulative antischistosomal efficacy and toxicity of one and two additional courses of artesunate-mefloquine (measured in a similar way as for the primary outcomes, but at week 10 and 16 (i.e. 4 weeks after each additional course of artesunate-mefloquine), and (3) to monitor the incidence of clinical malaria (by capturing any clinical malaria diagnosed among the participants at the health facilities of the selected villages during the study period) and explore <i>P. falciparum</i> malaria infection and possible emergence of resistant markers (assessed by the proportion of (asymptomatic) malaria infection diagnosed in trial participants by molecular methods at inclusion and at the 6-month assessment, as well as the presence and frequency of markers of parasite resistance).</p>